Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aligos Therapeutics, Inc.

4.68
+0.11002.41%
Post-market: 4.45-0.2300-4.91%19:58 EDT
Volume:79.00K
Turnover:363.62K
Market Cap:28.61M
PE:-0.22
High:4.79
Open:4.61
Low:4.42
Close:4.57
Loading ...
Mar 10, 2025

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Mar 10, 2025

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 10, 2025

Major Issues Report

Form 8-K - Current report
Feb 12, 2025

Major Issues Report

Form 8-K - Current report
Feb 03, 2025

Major Issues Report

Form 8-K - Current report
Nov 15, 2024

Correspondence

Form CORRESP - Correspondence
Nov 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Nov 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Nov 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Nov 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Nov 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Nov 12, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Nov 06, 2024

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Nov 06, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 06, 2024

Major Issues Report

Form 8-K - Current report
Sep 12, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Sep 05, 2024

Major Issues Report

Form 8-K - Current report
Aug 20, 2024

Major Issues Report

Form 8-K - Current report
Aug 09, 2024

Major Issues Report

Form 8-K - Current report
Aug 06, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]